FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000600513> ?p ?o ?g. }

• W2000600513 endingPage "459" @default.
• W2000600513 startingPage "449" @default.
• W2000600513 abstract "To evaluate safety in an interim analysis of transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEB) in 13 patients with hepatic metastases from neuroendocrine tumors (NETs) as part of a phase II trial. Institutional Review Board approval and informed consent were obtained. Thirteen patients completed preliminary safety analysis. Their mean age was 65 years, Eastern Cooperative Oncology Group status was 0/1, tumor burden range was 4–75 %, and mean targeted tumor size was 5.9 cm. Up to four DEB-TACE sessions (100–300 μm beads loaded with ≤100 mg doxorubicin) within 6 months were allowed. Tumor response was assessed by magnetic resonance imaging 1 month after treatment using contrast-enhancement [European Association for the Study of the Liver (EASL) and size Response Evaluation Criteria in Solid Tumors (RECIST)] criteria. Safety was assessed by National Cancer Institute Common Terminology Criteria. DEB-TACE was successfully performed in all 13 patients. At 1 month follow-up, there was a mean 12 % decrease in tumor size (p < 0.0003) and a 56 % decrease in tumor enhancement (p < 0.0001). By EASL criteria, the targeted lesion objective response rate was 78 %. Grade 3 to 4 toxicities were fatigue (23 %), increased alanine amino transferase (15 %), hyperglycemia (15 %), and abdominal pain (8 %). Seven patients developed bilomas (54 %); all of these patients had multiple small (<4 cm) lesions. Subsequently, four underwent percutaneous drainage, three for abscess formation and one for symptoms related to mass effect. Although biloma and liver abscess are known risks after TACE, the high incidence in our study population was unexpected and forced interruption of the trial. Although this occurred in a small group of patients, we have changed our technique and patient selection as a result of these findings, thus allowing resumption of the trial." @default.
• W2000600513 created "2016-06-24" @default.
• W2000600513 creator A5035913031 @default.
• W2000600513 creator A5038707648 @default.
• W2000600513 creator A5039776680 @default.
• W2000600513 creator A5058146274 @default.
• W2000600513 creator A5061760121 @default.
• W2000600513 creator A5065695204 @default.
• W2000600513 creator A5067085754 @default.
• W2000600513 date "2012-06-22" @default.
• W2000600513 modified "2023-10-11" @default.
• W2000600513 title "Phase II Study of Chemoembolization With Drug-Eluting Beads in Patients With Hepatic Neuroendocrine Metastases: High Incidence of Biliary Injury" @default.
• W2000600513 cites W1532334298 @default.
• W2000600513 cites W1922426788 @default.
• W2000600513 cites W1966448677 @default.
• W2000600513 cites W1969348024 @default.
• W2000600513 cites W1974105707 @default.
• W2000600513 cites W1974264673 @default.
• W2000600513 cites W1989709794 @default.
• W2000600513 cites W1990026158 @default.
• W2000600513 cites W1990509102 @default.
• W2000600513 cites W1991443468 @default.
• W2000600513 cites W1994118064 @default.
• W2000600513 cites W2003860294 @default.
• W2000600513 cites W2014356332 @default.
• W2000600513 cites W2020305814 @default.
• W2000600513 cites W2020465877 @default.
• W2000600513 cites W2020830322 @default.
• W2000600513 cites W2021228878 @default.
• W2000600513 cites W2032215458 @default.
• W2000600513 cites W2038487138 @default.
• W2000600513 cites W2039621565 @default.
• W2000600513 cites W2043103956 @default.
• W2000600513 cites W2047757951 @default.
• W2000600513 cites W2050344385 @default.
• W2000600513 cites W2055037251 @default.
• W2000600513 cites W2068873885 @default.
• W2000600513 cites W2069932251 @default.
• W2000600513 cites W2076835654 @default.
• W2000600513 cites W2082891425 @default.
• W2000600513 cites W2092759077 @default.
• W2000600513 cites W2093580610 @default.
• W2000600513 cites W2107457664 @default.
• W2000600513 cites W2107492854 @default.
• W2000600513 cites W2115754856 @default.
• W2000600513 cites W2122583281 @default.
• W2000600513 cites W2138059780 @default.
• W2000600513 cites W2139248078 @default.
• W2000600513 cites W2163486683 @default.
• W2000600513 cites W2533556634 @default.
• W2000600513 doi "https://doi.org/10.1007/s00270-012-0424-y" @default.
• W2000600513 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3596485" @default.
• W2000600513 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22722717" @default.
• W2000600513 hasPublicationYear "2012" @default.
• W2000600513 type Work @default.
• W2000600513 sameAs 2000600513 @default.
• W2000600513 citedByCount "87" @default.
• W2000600513 countsByYear W20006005132012 @default.
• W2000600513 countsByYear W20006005132013 @default.
• W2000600513 countsByYear W20006005132014 @default.
• W2000600513 countsByYear W20006005132015 @default.
• W2000600513 countsByYear W20006005132016 @default.
• W2000600513 countsByYear W20006005132017 @default.
• W2000600513 countsByYear W20006005132018 @default.
• W2000600513 countsByYear W20006005132019 @default.
• W2000600513 countsByYear W20006005132020 @default.
• W2000600513 countsByYear W20006005132021 @default.
• W2000600513 countsByYear W20006005132022 @default.
• W2000600513 countsByYear W20006005132023 @default.
• W2000600513 crossrefType "journal-article" @default.
• W2000600513 hasAuthorship W2000600513A5035913031 @default.
• W2000600513 hasAuthorship W2000600513A5038707648 @default.
• W2000600513 hasAuthorship W2000600513A5039776680 @default.
• W2000600513 hasAuthorship W2000600513A5058146274 @default.
• W2000600513 hasAuthorship W2000600513A5061760121 @default.
• W2000600513 hasAuthorship W2000600513A5065695204 @default.
• W2000600513 hasAuthorship W2000600513A5067085754 @default.
• W2000600513 hasBestOaLocation W20006005132 @default.
• W2000600513 hasConcept C126322002 @default.
• W2000600513 hasConcept C126838900 @default.
• W2000600513 hasConcept C141071460 @default.
• W2000600513 hasConcept C143409427 @default.
• W2000600513 hasConcept C2776694085 @default.
• W2000600513 hasConcept C2777035434 @default.
• W2000600513 hasConcept C2778019345 @default.
• W2000600513 hasConcept C2779066768 @default.
• W2000600513 hasConcept C2779690883 @default.
• W2000600513 hasConcept C2779984678 @default.
• W2000600513 hasConcept C2780400711 @default.
• W2000600513 hasConcept C2781464078 @default.
• W2000600513 hasConcept C2908647359 @default.
• W2000600513 hasConcept C31760486 @default.
• W2000600513 hasConcept C500558357 @default.
• W2000600513 hasConcept C513090587 @default.
• W2000600513 hasConcept C535046627 @default.
• W2000600513 hasConcept C61943457 @default.
• W2000600513 hasConcept C71924100 @default.
• W2000600513 hasConcept C99454951 @default.

• next